Status:
UNKNOWN
Extent of Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
Lead Sponsor:
Samsung Medical Center
Conditions:
Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Occult lymph node metastasis is common in micro papillary thyroid cancer. However, the role of lymph node dissection in the treatment of microPTC remains controversial. The investigators want to inves...
Detailed Description
The investigators will assign all patients to three groups; no dissection group (Group I), sentinel lymph node biopsy only group (Group II) and routine central neck dissection group (Group III). At fi...
Eligibility Criteria
Inclusion
- papillary carcinoma of thyroid (less than 4cm)
- no evidence of lymph node metastasis in preoperative work-up result
- the patients who accept this study
Exclusion
- large thyroid cancer( \> 4cm)
- morbid
- anticoagulation agent usage
- endoscopic or robotic thyroid operation
- evidence of lymph node metastasis or extrathyroidal extension in preoperative US and CT scan
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT01149161
Start Date
May 1 2009
End Date
December 1 2020
Last Update
April 21 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710